代谢重编程有助于膀胱癌的发展。本研究旨在了解SLC7A5在膀胱癌中的作用。我们通过生物信息学、蛋白质印迹、细胞周期分析、细胞增殖实验和侵袭实验等多种方法系统分析了SLC7A5与膀胱癌的相关性。我们还研究了肿瘤微环境 (TME) 内的免疫学特征，包括癌症免疫周期、免疫调节剂、免疫检查点、肿瘤浸润免疫细胞 (TIIC)、T 细胞炎症评分和治疗反应。此外，为了全面评估SLC7A5的表达模式和免疫学作用，使用癌症基因组数据集进行了泛癌分析。SLC7A5与膀胱癌患者的不良预后相关，激活Wnt通路并促进膀胱癌细胞周期进展，扩散、迁移和入侵。基于SLC7A5与免疫调节剂、TIIC、癌症免疫周期、免疫检查点和T细胞炎症评分呈正相关的证据，我们还发现SLC7A5与炎症性肿瘤免疫微环境相关。 EGFR靶向治疗、癌症免疫治疗和放射治疗对SLC7A5高表达的膀胱癌患者有效。然而，低SLC7A5患者对靶向治疗和抗血管生成治疗敏感，例如阻断β-连环蛋白网络、PPAR-γ和FGFR3信号传导。抗 SLC7A5 与癌症免疫疗法相结合可能比单独使用任何一种疗法具有更好的效果。此外，我们在多种癌症的TME中观察到SLC7A5的特异性过表达。SLC7A5可以预测膀胱癌患者对免疫治疗、放疗和化疗的治疗反应。靶向 SLC7A5 与免疫疗法相结合可能是一种潜在合适的治疗选择。© 2024。作者。

Metabolic reprogramming contributes to bladder cancer development. This study aimed to understand the role of SLC7A5 in bladder cancer.We systematically analyzed the correlation between SLC7A5 and bladder cancer through various approaches, including bioinformatics, western blotting, cell cycle analysis, cell proliferation assays, and invasion experiments. We also investigated the immunological features within the tumor microenvironment (TME), encompassing cancer immune cycles, immune modulators, immune checkpoints, tumor-infiltrating immune cells (TIIC), T cell inflammation scores, and treatment responses. Additionally, for a comprehensive assessment of the expression patterns and immunological roles of SLC7A5, pan-cancer analysis was performed using cancer genomics datasets.SLC7A5 was associated with adverse prognosis in bladder cancer patients, activating the Wnt pathway and promoting bladder cancer cell cycle progression, proliferation, migration, and invasion. Based on the evidence that SLC7A5 positively correlated with immunomodulators, TIIC, the cancer immune cycle, immune checkpoint and T cell inflammation scores, we also found that SLC7A5 was associated with the inflammatory tumor immune microenvironment. EGFR-targeted therapy, cancer immunotherapy, and radiation therapy were effective for patients with high SLC7A5 expression in bladder cancer. Low SLC7A5 patients were, however, sensitive to targeted therapies and anti-angiogenic therapy, such as blocking β-catenin network, PPAR-γ and FGFR3 signaling. Anti-SLC7A5 combined with cancer immunotherapy may have greater effectiveness than either therapy alone. Furthermore, we observed specific overexpression of SLC7A5 in TME of various cancers.SLC7A5 can predict therapeutic response to immunotherapy, radiotherapy and chemotherapy in bladder cancer patients. Targeting SLC7A5 in combination with immunotherapy may be a potentially appropriate treatment option.© 2024. The Author(s).